

ORIGINAL RESEARCH

OPEN ACCESS
Full open access to this and thousands of other papers at <http://www.la-press.com>.

Increased Serum Cu/Zn SOD in Individuals with Bipolar Disorder

A.J. Russo

Research Director, Health Research Institute/Pfeiffer Treatment Center, Warrenville, Illinois 60555, USA.
Corresponding author email: ajrusso@hriptc.org

Abstract

Aim: To assess serum Cu/Zn SOD (Superoxide Dismutase) concentration in individuals with bipolar disorder.

Subjects and methods: Serum from 20 individuals diagnosed with bipolar disorder and 20 age and gender similar controls were tested for Cu/Zn SOD serum concentration using ELISAs.

Results: Serum Cu/Zn SOD levels of individuals with bipolar disorder were significantly higher than age and gender matched controls.

Discussion: These results suggest an association between Cu/Zn SOD serum levels and bipolar disorder.

Keywords: bipolar disorder, Cu/Zn SOD, superoxide dismutase, oxidative stress

Proteomics Insights 2010:3 1–6

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.



Introduction

Bipolar disorder is characterized by episodes of mania and depression that are frequently acute, debilitating, and conducive to gross social dysfunction and an elevated suicide rate.¹⁻⁴ While often lifelong and affecting about 1.5% of the population, the condition responds to, and in some cases is controlled by, pharmacologic treatment—particularly with mood-stabilizing agents.

Recent findings indicate that the pathologic process of this disorder is involved in complex interactions between multiple susceptibility genes and environmental factors.^{5,6} Recent advances in genetics, molecular and cellular biology, molecular neuroscience, and imaging technology have provided a variety of new and sophisticated approaches to evaluate the complex features of this disease. These new molecular genetic, molecular pharmacologic, and molecular and cellular biological approaches to the study of the etiology of psychiatry disorders and the mechanism of action of psychotropic drugs have been very instructive in refining our understanding. Given the many widely used advances in investigative approaches and technologies, the term “molecular psychiatry” has been readily adopted to replace the older “biological psychiatry”.

Important among these advances, high density DNA expression microarray technology has recently been widely adapted by scientists in the search for susceptibility genes for bipolar disorder.⁷⁻⁹ Gene candidates coding for proteins related to mitochondrial function and apoptosis, glutamate receptors, markers of GABAergic neurons, molecular chaperones, and oligodendrocyte proteins are differentially expressed in postmortem brain tissue, peripheral blood cells, and olfactory neuroepithelium between control and bipolar disorder subjects.¹⁰⁻¹²

Oxidative damage results from biochemical interactions between reactive oxygen species (ROS) and target biomolecules. ROS can damage nucleic acids, lipids, and proteins, and figures prominently in the etiology and progression of numerous cancers¹³⁻¹⁵ as well as coronary and carotid atherosclerosis.¹⁶⁻¹⁹

Oxidative stress, occurring as a consequence of imbalance between the formation of free oxygen radicals and inactivation of these species by antioxidant defense system, is capable of causing damage

to various cellular and extracellular constituents. The deleterious effects of increased oxidative stress are termed oxidative damage. These effects generally appear after exposure to a relatively high concentration of reactive oxygen species (ROS) and/or a decrease in antioxidant (AO) defense system against ROS.²⁰

In vivo, oxygen radicals are produced as by products of normal oxidative metabolism.²¹ Hence, activated cells with increased metabolism produce more oxygen radicals. It has long been known that control of the intracellular redox environment is vital for proper cellular function. To protect themselves from the constant oxidative challenge, cells have developed defense mechanisms that ensure a proper balance between pro- and antioxidant molecules.²²

There are three major families of superoxide dismutase, depending on the metal cofactor: Cu/Zn (which binds both copper and zinc),^{23,24} Fe and Mn types (which bind either iron or manganese),²⁵ and finally the Ni type, which binds nickel.²⁶

Cu/Zn superoxide dismutase (SOD-1) is a key enzyme in the dismutation of superoxide radicals resulting from cellular oxidative metabolism, converting them into hydrogen peroxide,²⁷ and, as a result, serves a key antioxidant role. In fact, mice lacking SOD die several days after birth, amidst massive oxidative stress.²⁸ Copper, and zinc participate in SOD enzymatic mechanisms that protect against free radicals and therefore serve an important adjunct role in oxidative balance.²⁹

Oxidative stress has been implicated as an etiological factor in Bipolar Disorder.³⁰⁻³³ Because Cu/Zn SOD is a major mitochondrial anti-oxidant, this study was designed to determine Cu/Zn SOD serum levels in individuals with bipolar disorder and test the hypothesis that this oxidative stress marker is increased in this group.

Materials and Methods

ELISA to measure serum Cu/Zn SOD (Bender MedSystems, eBioscience, San Diego CA)

All reagents and specimens were equilibrated to room temperature before the assay was performed. A 1:51 dilution of the patient samples was prepared by mixing 10 μ l of the patient's sera with 0.5 ml of Serum



Diluent. One hundred microliters of calibrators (0.08–2.5 ng/ml Cu/Zn SOD), serum diluent alone, and diluted patient samples were added to the appropriate microwells of a microculture plate (each well contained affinity purified polyclonal IgG to Cu/Zn SOD). Wells were incubated for 60 minutes (± 5 min) at room temperature, then washed 4x with wash buffer. One hundred microliters of pre-diluter anti-human Cu/Zn SOD IgG conjugated with HRP was added to all microwells, incubated for 30 minutes (± 5 min) at room temperature, then wash 4x with wash buffer. One hundred microliters of enzyme substrate was added to each microwell. After approximately 30 minutes at room temperature, the reaction was stopped by adding 50 μ l of 1M sulfuric acid, then the wells were read at 450 nm with an ELISA reader (BioRad Laboratories, Inc., Hercules, CA, USA).

Subjects

Experimental and controls

Serum from individuals with diagnosed bipolar disorder, all fulfilling DSM-IV diagnostic criteria ($n = 20$; 17 male; mean age 34 ± 12 years), and controls ($n = 20$; 17 male mean age 47 ± 14 years) was obtained from patients presenting at the Health Research Institute/Pfeiffer Treatment Center. Most of these individuals were diagnosed using The Mood Disorder Questionnaire before presenting at the Pfeiffer Treatment Center, Warrenville, IL.*

Patients ($n = 20$) for this study were chosen randomly as they presented to The Pfeiffer Treatment Center. At the time of the blood draw, three were taking anti-depressants, two were taking anti-epileptic drugs, four were taking anti-psychotics, four were taking lithium and seven presented not taking any associated drugs. We did not find any significant difference in HGF serum concentration in any of these groups (ANOVA; $P = 0.995$; $F = 0.157$). All patients presented after having mixed manic and depression episodes.

Controls were normal healthy volunteers, all employees of the Pfeiffer Treatment Center.

* The Pfeiffer Treatment Center is a comprehensive treatment and research center, specializing in the care of with neurological disorders, including bipolar disorder.

Serums

All serums, experimental and control serums were treated in an identical fashion—frozen at -70°C immediately after collection and cell/serum separation, then stored at -70°C until thawed for use in ELISAs.

Statistics

Inferential statistics were derived from t-test and odds ratios with 95% confidence intervals.

Results

Serum from 20 individuals diagnosed with bipolar disorder and 20 age and gender similar controls was tested for Cu/Zn SOD plasma concentration using an ELISA (described above). Each assay was repeated two or more times, with multiple wells for each serum in each assay. Results of a typical assay with assay controls are shown in Figure 1, and Bipolar and control individuals are shown in Figure 2. These data reflect the low variability and high reliability of each assay.

Serum Cu/Zn SOD levels of 20 Bipolar individuals were significantly higher (mean = 1.437 ng/ml) than the 20 non-depressed controls (mean = 0.360 ng/ml) ($P < 0.0001$) (Table 1).

We found no relationship between age and Cu/Zn SOD levels (Fisher F value = 0.374; $P = 0.865$).

Discussion

Oxidative stress has been implicated in the pathogenesis of a diverse group of disease states, and, because the brain has comparatively greater vulnerability to oxidative damage, may be a common pathogenic mechanism underlying many major psychiatric disorders.

This study represents an attempt to assess levels of the oxidative damage expressed by Cu/Zn SOD levels in the plasma of individuals with bipolar disorder, but otherwise healthy adults. As our results demonstrate, compared with similar control subjects, although each individual's Cu/Zn SOD level differed, the mean of those with clinical depression show significantly higher serum levels of Cu/Zn SOD.

We did not find any relationship between pharmacological treatment and Cu/Zn SOD levels. This is most likely because of the preliminary nature of




Figure 1. Cu/Zn SOD controls: Typical ELISA.

this study. We will update this possible relationship as more patients are studied.

Other studies have shown positive correlations between oxidative stress markers and bipolar disorder^{34,35} and have suggested a role of mitochondrial dysfunction in the etiology of the disease.³⁶

Mitochondria-related genes may be abnormally expressed in bipolar disorder. Increasing evidence has shown the presence of mitochondrial dysfunctions such as deletion, mutation and abnormal expression of mitochondria-related genes, increased anaerobic glycolysis, and impaired phospholipid metabolism.

Because mitochondrial oxidative phosphorylation is the major resource for the generation of reactive oxygen species, mitochondrial dysfunction indicates that oxidative stress may occur in bipolar disorder and that oxidative stress induced damage may be prevented by mood-stabilizing treatment.³⁷ This dysfunction may be directly associated with the high amounts Cu/Zn SOD in bipolar individuals observed in this study.

The present data supports the recent finding by Kunz et al²³ that Cu/Zn SOD is raised in euthymic bipolar patients and raises the intriguing possibility that the increase in Cu/Zn SOD levels in




Figure 2. Cu/Zn SOD serum concentration (ng/ml) bipolar and controls: Typical ELISA.

**Table 1.** Cu/Zn SOD significantly higher in bipolar compared to controls.

Group	Cu/Zn SOD bipolar	Cu/Zn SOD controls
Mean	1.437	0.360
SD	0.632	0.185
SEM	0.141	0.041
N	20	20

Note: The two-tailed *P* value is less than 0.0001; *t* = 7.3114; *df* = 38; standard error of difference = 0.147.

bipolar disorder could be mechanistically related to increased oxidative stress associated with mitochondrial dysfunction. Correcting the oxidative imbalance in BD may offer a new means of controlling the detrimental effects of mood episodes on cognition and bodily systems, and, if it also prevented the associated increase in Cu/Zn SOD, it would provide more direct evidence for the hypothesized causal relationship between increased oxidative stress and this potential marker.

The clinical relevance of increased oxidative damage, evidenced in bipolar individuals, is currently unknown, and future studies should appropriately address this deficit. Our data are consistent with the hypothesis that oxidative damage is a potential common pathophysiological mechanism underlying multiple co-morbid conditions in bipolar individuals. Future studies should include measurement of multiple oxidative damage markers to different macromolecules, associated dietary deficiencies associated with these markers, associated severity of bipolar disease, and should address whether bipolar disease remission remediates underlying oxidative damage.

Acknowledgements

I'd like to thank Scott Filer, Executive Director of The Pfeiffer Treatment Center and Dr. Robert deVito, MD for their support and help in this research and manuscript preparation.

I'd also like to thank Laurie Myers and Kyle Andrews for their technical assistance.

Disclosure

This manuscript has been read and approved by the author. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The author and peer reviewers of this paper report no conflicts of interest. The author

confirms that they have permission to reproduce any copyrighted material.

References

1. Tondo L, Isacson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. *CNS Drugs*. 2003;17:491–511.
2. Manji HK, Lenox RH. The nature of bipolar disorder. *J Clin Psychiatry*. 2000;61 Suppl 13:42–57.
3. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. *J Affect Disord*. 2002;68:167–81.
4. Moller HJ, Curtis VA. The bipolar spectrum: diagnostic and pharmacologic considerations. *Expert Rev Neurother*. 2004;6 Suppl 2:S3–8.
5. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. *Neurochem Int*. 2007;50:461–90.
6. Sanders AR, Duan J, Gejman PV. Complexities in psychiatric genetics. *Int Rev Psychiatry*. 2004;16:284–93.
7. Sun X, Wang JF, Tseng M, et al. Down regulation in components of mitochondrial electron transport chain in post-mortem frontal cortex from subjects with bipolar disorder. *J Psychiatry Neurosci*. 2006;31:189–96.
8. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. *Arch Gen Psychiatry*. 2004;61:300–8.
9. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Hum Mol Genet*. 2005;14:241–53.
10. Nguyen DV, Arpat AB, Wang N, et al. DNA microarray experiments: biological and technological aspects. *Biometrics*. 2002;58:701–17.
11. Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. *Trends Genet*. 2006;22:101–9.
12. Konradi C. Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. *Brain Res Brain Res Rev*. 2005;50:142–55.
13. Kato T, Kakiuchi C, Iwamoto K. Comprehensive gene expression analysis in bipolar disorder. *Can J Psychiatry*. 2007;52(12):763–71.
14. Marnett LJ. Oxyradicals and DNA damage. *Carcinogenesis*. 2000;21:361–70.
15. Floyd RA. The role of 8-hydroxyguanine in carcinogenesis. *Carcinogenesis*. 1990;11:1447–50.
16. Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. *Trends Cardiovasc Med*. 2003;13:270–5.
17. Botto N, Masetti S, Petrozzi L, et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. *Coron Artery Dis*. 2002;13:269–74.
18. Martinet W, Knaapen MWM, de Meyer GRY, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. *Circulation*. 2002;106:927–32.
19. Botto N, Rizza A, Colombo MG, et al. Evidence for DNA damage in patients with coronary artery disease. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2001;493:23–30.
20. Sies H. Oxidative stress: Oxidants and Antioxidants. Academic Press; New York: 1991.
21. Malmstrom BG. Enzymology of oxygen. *Annu Rev Biochem*. 1982;51:21.
22. Forman HJ, Torres M. Redox signaling in macrophages. *Mol Aspects Med*. 2001;22:189.
23. Richardson JS, Thomas KA, Rubin BH, Richardson DC. Crystal Structure of Bovine Cu/Zn Superoxide Dismutase at 3 Å Resolution: Chain Tracing and Metal Ligands. *Proc Natl Acad Sci U S A*. 1975;72:1349–53.
24. Tainer JA, Getzoff ED, Richardson JS, Richardson DC. Structure and mechanism of copper, zinc superoxide dismutase. *Nature*. 1983;306(5940):284–7.
25. Li Y, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nature Genetics*. 1995;11:376–81.



26. Miller A. Superoxide dismutases: active sites that save, but a protein that kills. *Current Opinion in Chemical Biology*. 2004;8:162–8.
27. Fridovich I. The biology of oxygen radicals. *Science*. 1978;201:875.
28. Bonham M, O'Connor JM, Hannigan BM, Strain JJ. The immune system as a physiological indicator of marginal copper status? *Br J Nutr*. 2002;87(5):393–403.
29. Ozcelik D, et al. Copper-mediated oxidative stress in rat liver. *Biological Trace Element Research*. 2007;96:209–15.
30. Frey BN, et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007;31(1):283–5.
31. Steckert AV, et al. Role of oxidative stress in the pathophysiology of bipolar disorder. *Neurochem Res*. 2010;doi 10.1007/s11064-010-0195-2.
32. Belmaker RH. Bipolar disorder. *N Engl J Med*. 2004;351:476–86.
33. Frey BN, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. *J Psychiatry Neurosci*. 2006 Sep;31(5):326–32.
34. Andreatza A, et al. Oxidative stress markers in bipolar disorder: A meta-analysis. *J of Affective Disorders*. 2008;2:135–44.
35. Gama C. Markers of oxidative stress in bipolar disorder and in schizophrenia. *European Psychiatry*. 2009;24:S159.
36. Andreatza A. Mitochondrial dysfunction and oxidative stress in bipolar disorder. *European Psychiatry*. 2009;24:S15.
37. Wang JF. Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. *Can J Psychiatry*. 2007;52(12):753–62.

Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

<http://www.la-press.com>